Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
LY3884961 for Gaucher Disease
Recruiting1 awardPhase 1 & 2
Fairfax, Virginia
This trial is a Phase 1/2, multicenter, open-label study of LY3884961, which is being evaluated for safety and tolerability in adults with peripheral manifestations of GD. Up to 3 dose levels of LY3884961 will be assessed in 3 dose-finding cohorts of 3 patients, and then up to 6 patients may be enrolled into an expansion cohort. For each enrolled patient, the study will last approximately 5 years, including up to a 45-day screening period. During the first 18 months after dosing, subjects will be evaluated for the effects of LY3884961 on safety, tolerability, immun
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.